Apyx Medical has demonstrated impressive financial growth in the first quarter of 2026, with total revenue climbing to $12.5 million, an increase from $9.4 million in the same period last year. This notable surge is primarily fueled by the strong performance of its Surgical Aesthetics segment and the successful market integration of its AYON body contouring system, which became commercially available in September 2025.

Chief Executive Officer Charlie Goodwin highlighted that the company's first-quarter achievements were a testament to the robust adoption of the AYON system in the U.S., sustained global demand for single-use handpieces, and a rise in Renuvion generator sales internationally. The Surgical Aesthetics division alone saw a 36% year-over-year revenue increase, reaching $10.7 million. Goodwin further emphasized that the AYON system's rollout is still in its nascent stages, despite strong engagement from both existing and new clients, driven by increasing market awareness and confidence in the product's capabilities. The company is also anticipating FDA 510(k) clearance for power liposuction on the AYON platform this quarter, a move expected to enhance the system's versatility and broaden its customer base.

Internationally, Apyx Medical experienced significant expansion, with overseas revenue soaring by 63% to $4.4 million, while domestic revenue grew by 20% to $8.1 million. The company reported strong initial success in South Korea following regulatory approval in December 2025, surpassing initial demand expectations. Apyx plans to register AYON globally, focusing on key regions such as Europe, Latin America, the Middle East, and Asia. Financially, the company reported an improved gross profit of $7.9 million, up from $5.7 million year-over-year, and a narrowed operating loss, signaling enhanced operational efficiency and strategic financial management. Consequently, Apyx has revised its full-year 2026 revenue forecast upwards, reflecting optimism about continued growth, particularly in Surgical Aesthetics, and its ability to manage market challenges like tariffs through diversified manufacturing.

Apyx Medical's strategic focus on innovation and global market penetration positions it for sustained growth. The company's commitment to expanding its product capabilities and addressing evolving market needs, such as skin tightening solutions post-weight loss, demonstrates a forward-thinking approach. This dedication to progress, coupled with sound financial stewardship, empowers Apyx to not only achieve its business objectives but also make meaningful contributions to the medical aesthetics field, enhancing patient care and technological advancement worldwide.